NAVIDEA BIOPHARMACEUTICALS, INC. Warrant To Purchase Common StockWarrant Agreement • August 2nd, 2022 • Navidea Biopharmaceuticals, Inc. • In vitro & in vivo diagnostic substances • New York
THIS WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”), is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (Eastern Time) on _____, 20271 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Navidea Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant shall initially be issued and maintained in the form of a security held in book-entry form and the Depository Trust Company or its nominee (“DTC”) shall initially be the sole registered holder of this Warrant, subject to Holde
WARRANT AGENCY AGREEMENTWarrant Agency Agreement • August 2nd, 2022 • Navidea Biopharmaceuticals, Inc. • In vitro & in vivo diagnostic substances • New York
WARRANT AGENCY AGREEMENT, dated as of August [ ], 2022 (“Agreement”), by and between Navidea Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), and Continental Stock Transfer & Trust Company, a New York corporation (the “Warrant Agent”).
NAVIDEA BIOPHARMACEUTICALS, INC. DEALER-MANAGER AGREEMENTDealer-Manager Agreement • August 2nd, 2022 • Navidea Biopharmaceuticals, Inc. • In vitro & in vivo diagnostic substances • New York
The following will confirm our agreement relating to the proposed rights offering (the “Rights Offering”) to be undertaken by Navidea Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), pursuant to which the Company will distribute to holders of record of its common stock, par value $0.001 per share (the “Common Stock”) and to holders of the outstanding warrants issued to the underwriter in our public offering in 2019, Series D Preferred Stock, and Series F Preferred Stock (the “Participating Securities”), subscription rights (the “Rights”) to subscribe for up to an aggregate of 35,000 units (the “Units”), each Unit consisting of one share of Series I Convertible Preferred Stock, par value $0.001 per share (the “Rights Shares”) and one warrant, with each warrant representing the right to purchase 1,538 shares of Common Stock (the “Rights Warrants” and the Rights Shares, the Rights Warrants and the shares of Common Stock issuable upon conversion of the Rights Shares and ex
